Vaccines for Hypertension Disorder: Beneficial or Detrimental
The prevalence of hypertension in the adult population was estimated to be 26.4% in 2000 and is projected to be 29.2% by 2025. Hypertension significantly increases the risk of developing disorders such as coronary artery disease, stroke, arrhythmia, heart failure, abnormal renal function and many other complications associated with structural damage to the cardiovascular system, hence the management of hypertension is very essential. Management of hypertension involves different approaches like life style modification and antihypertensive therapy. Life style modifications like weight reduction, discontinue smoking, limiting alcohol intake, increasing physical activity, reducing salt intake, increasing fruit vegetable intake, decreasing saturated and total fat intakes helps in managing hypertension. Antihypertensive therapy without co-morbidities involves administration of different classes of drugs like diuretics, angiotensin convertase enzyme, angiotensin receptor blockers, β blockers, calcium channel blockers, aldosterone antagonist and rennin inhibitors to achieve desired blood pressure intiating treatment with two drug combination may allow blood pressure targets to be reached earlier than monotherapy. This may lead to various adverse effects. Both the approaches requires patient adherence, which is a major problem in management of hypertension. To overcome the problem of patient compliance, research is going on the development of vaccines for hypertension, which produces antibodies against endogenous renin/angiotensin I and II. Vaccines for treatment of hypertension unlike other conventional, vaccine which is used for prevention of various diseases. Although, the concept is intriguing because excessive stimulation of immune system against endogenous substance may lead to autoimmune disorder like nephritis and also renin angiotensin system involved in the maintaining of homeostasis will be hampered. Its better to use many excellent therapeutic options that are already available to inhibit the RAS, until efficient vaccine is developed.
Received: June 28, 2010;
Accepted: July 23, 2010;
Published: September 30, 2010
Hypertension is defined as a sustained increase in systolic blood pressure (SBP) of 140 mmHg or greater and/or diastolic blood pressure (DBP) of 90 mmHg or greater. Hypertension is classified into two types, i.e., Primary or essential hypertension (no underlying cause) and secondary hypertension (hypertension due to other disorders like kidney disease, vascular or endocrine disorders).
Management of hypertension
Lifestyle modification: Healthy lifestyles by an individual are important
for the prevention of high BP and which is also essential for management of
those with hypertension (Whelton et al., 2002).
|| Classes of drugs used for hypertension
Reducing weight if overweight (Weight loss of as little as 10 lb reduces BP
and/or prevents hypertension in a large proportion of overweight persons) and
maintaining the ideal body weight (He et al., 2000),
stop smoking, limiting alcohol intake, increasing physical activity, reducing
salt intake, increasing fruit-vegetable intake, decreasing saturated and total
fat intakes helps in managing hypertension (Chobanian et
Antihypertensive therapy: The ultimate goal of antihypertensive therapy
is to reduce cardiovascular mortality and renal morbidities. The decision to
start antihypertensive treatment should be based on two criteria, i.e., the
level of systolic and diastolic BP and the level of cardiovascular risk. Most
persons with hypertension especially those >50 years of age, will reach the
DBP goal once the SBP goal is achieved, the primary focus should be on attaining
the SBP goal (Franklin et al., 2001).
The Blood Pressure (BP) goal (SBP/DBP) for hypertension associated with cardiovascular
disease complication and renal disease is <140/90 and <130/80 mmHg, respectively.
Hypertension without co-morbidities can be treated by selecting any of these
5 classes of drugs include diuretics, beta-blockers, calcium channel blockers,
angiotensin converting enzyme inhibitors and angiotensin receptor blockers (Table
1) (Chobanian et al., 2003).
Combination therapy: Initiating therapy with two drug combination may
allow BP targets to be reached earlier than monotherapy. In high-risk hypertensives,
9 out of 10 patients require two or more antihypertensives to reduce their BP
to <140/90 mmHg. When BP is more than 20/10 mmHg above the goal, consideration
should be given to initiate therapy with two drugs (Sica,
2002). There are various fixed dose combinations for treatment of hypertension
among them very few is recommended (Table 2).
In present days, the number of patients suffering from disorders like diabetes
and associated comorbidities, i.e., atherosclerosis, dyslipidemia, hypertension
and other disorders is increasing world wide (Sathyanaryana
et al., 2008). In such cases there is a need of administration of
more than one drug for the treatment of these disorders, hence there is possibility
of drug-drug interactions.
A study of the mechanisms of drug interactions is of much value in selecting
the drug combinations to provide rational therapy. The drug interaction studies
assume much importance, especially for drugs that have a narrow margin of safety
and where the drugs are used for a prolonged period of time (Sultanpur
et al., 2010). Hypertension is one such disorder that needs treatment
for prolonged periods and maintenance of normal blood pressure is very important
in this condition because both hypertension and hypotension are unwanted phenomena.
Renin inhibitors: Aliskiren is the first renin inhibitor, binds competitively
to the active site of the enzyme. They interrupt the negative feedback effects
of angiotensin II on renin secretion; this increases renin concentrations, which
may attenuate the inhibition of the renin-angiotensin system by these therapies
(Duncan, 2009). Whether renin inhibitors offer therapeutic
benefits beyond those provided by ACE inhibitor and angiotensin receptor antagonist
therapies will require their direct comparison in clinical outcome studies.
Compliance to treatment: Non-compliance to treatment is the major problem involved in the treatment of hypertension. Various steps have been taken to over come the compliance (Table 3) to some extent these steps have been found to be useful.
Today we have drugs that are highly effective at lowering blood pressure with minimal side effects. However, above approaches lifestyle modification and antihypertensive therapy require patient adherence to be effective. Poor compliance is common for both approaches and is the main reason for inadequate blood-pressure control.
VACCINES FOR HYPERTENSION
Vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease causing microorganism and is often made from weakened or killed forms of the microbes or its toxins. The agent stimulates the bodys immune system to recognize the agent as foreign, destroys it and recognize it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Unlike conventional, vaccine for hypertension is not used for prevention but it is used for treatment of disease. it is named because they stimulate the immune system by acts on the renin angiotensin system.
Vaccine stimulates immune system and release antibodies against endogenous renin/angiotensin I/angiotensin II. If vaccination for high blood pressure were safe and effective in the long run, it might solve many problems. Besides resolving the compliance problem, the patients will not have to encounter the undesirable side effects of the drugs, would gain smooth, prolonged and progressive onset of action, increased diurnal control of blood pressure and reduction in drug interaction associated with conventional polypharmacy.
Therapeutic active vaccination targeting components of the RAS is a potential
option. It offers the possibility for reduction of blood pressure with two to
three immunizations per year. Such an approach could circumvent the need for
daily medication and substantially reduce the issue of patient compliance (Maurer
and Bachmann, 2010).
ROLE OF RENIN-ANGIOTENSIN SYSTEM
The Renin-Angiotensin System (RAS) is a well coordinated hormonal cascade in
the control of cardiovascular, renal and adrenal function that maintain homeostasis
and plays an imminent role in the regulation of arterial blood pressure (Akiyoshi
et al., 1993). Prof. Robert Tigerstedt and a noted Finnish physiologist
discovered the renin system in 1898 at the Karolinska Institute in Sweden (Ulfendahl
and Aurell, 1998).
Renin: Renin is an aspartyl proteolytic enzyme (Suh
et al., 2005) in juxtaglomerular cells of the afferent arteriole
of the kidney and is the locus for renin synthesis, storage and release. Translation
of renin mRNA in these cells produces pre prorenin, which in turn is then converted
to prorenin by the removal of a single peptide and glycosylation. Some of the
prorenin to renin conversion takes place in the juxtaglomerular cells, both
renin and prorenin are secreted from these cells. Prorenin is the more abundant
circulating form of renin (Beierwaltes, 2003).
The primary stimulatory intracellular second messenger for renin release is
the cyclic nucleotide c-AMP, which is probably the second messenger for stimulation
via beta-adrenergic nerves and prostaglandins. Active renin is secreted in response
to regulatory mechanisms: renal baroreceptor, macula densa and β1-receptor
stimulation via renal nerves and humoral factors (Duff et
Renin catalyzes the cleavage of leucine valine bond in the N-terminal region
of human angiotensinogen (large globular protein mainly derived from the pericentral
zone of liver lobules) or it cleaves a leucine bond in the angiotensinogen of
other species to produce the decapeptide angiotensin I (Suh
et al., 2005).
Angiotensins: Angiotensins are peptide hormones obtained by cleavage
of angiotensinogen by renin, which takes place in series of proteolytic reactions.
Angiotensin I doesnt have any biologic role, it serves as the precursor
of angiotensin II and III (Berk and Corson, 1997).
Angiotensin II is produced both systematically and locally in the vessel wall
by the actions of ACE, which cleaves angiotensin I to form angiotensin II. It
is the key effector hormone of the RAS, through the activation of small G proteins
such as Ras, Rho and Rac. It causes vasoconstriction, increases afterload, retention
of sodium and fluid, all of these actions affect the cardiovascular system and
increase the blood pressure (Duff et al., 1995).
It induces Vascular Smooth Muscle Cell (VSMC) remodeling, including proliferation,
migration and hypertrophy of the smooth muscle cells. Well-documented studies
on RASs role in the development and maintenance of arterial hypertension
have been implicated and also angiotensin II in cardiovascular and renal pathologies
(Unger et al., 1998).
Angiotensin II stimulate VSMC growth, increase expression of enzymes that produce
mediators of inflammation such as phospholipase A2, NAD(P)H oxidase,
stimulate the JAK/STAT pathway and activate gene transcription of such proto
oncogenes as c-fos (Schmieder et al., 2007).
Angio-tensin III is more lipid-soluble than angiotensin II, hence abundantly
found in the brain and cerebrospinal fluid. It has lower affinity for the angiotensin
II binding sites and also degrades more rapidly. Hence elicits less potency
than angiotensin II. Angiotensin has effects on the brain that suggest it has
a role in memory. It also stimulates the release of plasminogen activator inhibitor
from endothelial cells (Schmieder et al., 2007).
Angiotensin convertase enzyme: Angiotensin Converting Enzyme (ACE) is
a zinc metallopeptidase widely distributed on the surface of endothelial cells
and epithelial cells. It has role in regulating the levels of angiotensin II
and bradykinin (Brown and Vaughan, 1998).
Angiotensin II receptors: Angiotensin II have high affinity to receptor
AT1, AT2 and AT4 and produce cellular response
via signal transduction. The AT1 and AT2 receptors may
be having similar affinities for angiotensin II bit they have different effects
(Duprez, 2006). Angiotensin II binds to the AT1
receptor and this activates G protein-coupled phospholipase C (PLC).
The PLC is an essential enzyme for transmembrane signal transduction
by generating second messenger molecules like inositol triphosphate (IP3)
and diacylglycerol (DAG). The IP3 induces the release of Ca2+
from internal stores and DAG is the physiological activator of protein kinase.
Distribution of the AT1 receptor in the adult is ubiquitous, including
the vasculature, kidney, adrenal gland, heart, liver and brain. With some exceptions,
most of the pathologic cardiovascular effects of angiotensin II are mediated
through the AT1 receptor: hypertension, coagulation, inflammation
and vascular smooth muscle cell growth (Duff et al.,
Angiotensin II binding to the AT2 receptor activates a counter regulatory
pathway to induce vasorelaxation via activation of the kinin/No/cGMP system.
The AT2 receptor is abundant in the fetal brain, kidney mostly involved
in developmental processes in the fetus. The AT2 receptor reappears
in adults, it generally acts as a counterweight to the pathologic effects of
AT1, which inhibits angiotensin II induced growth and pro inflammatory
activity and also decreases arterial blood pressure (Duff
et al., 1995).
The AT1 and AT2 receptors share only 34% homology and
they have distinct signal transduction pathways. Evidence suggests that AT4
receptor produce its effects via angiotensin IV and is an important mediator
of the expression of plasminogen activator inhibitor-1 (Burnier,
Renin immunization (Table 4): Renin immunization is
active immunization against human rennin which was first attempted by Goldblatt
(1951). The administration of heterologous (hog) renin in man produced anti
renin antibody. These antibodies were ineffective against human renin and no
fall in blood pressure observed in hypertensive patients (Goldblatt,
In early studies, the active immunization against renin was the target in several
species, particularly hog renin in dogs and human renin in primates have been
studied with successful results. But interpretation of these studies was limited
by the impurity of the immunogen, absence of hormonal assays throughout the
experiment and problems of species specificity (Michel et
High titre of renin antibodies were found by active immunization with pure
human renin and Freunds adjuvant in normotensive marmosets. There was a complete
inhibition of endogenous plasma renin activity and decrease in blood pressure.
|| Types of vaccine for hypertension
But all marmosets presented an autoimmune disease with specificity to the
kidney (cellular inflammatory proliferation around the intrarenal arterial tree
and an interstitial nephritis) (Michel et al., 1990).
Later similar studies were performed in Spontaneously Hypertensive Rats (SHRs)
using pure mouse submandibular gland renin, which shares 80% homology with the
rat renin. Immunization with mouse submandibular gland renin in SHR, with Freunds
adjuvant, induced a normalization of blood pressure associated with a high titre
of antirenin antibodies. The total inhibition of the plasma renin activity associated
with significant decrease in aldosterone secretion. Unfortunately, these animals
also presented an autoimmune disease of the kidney (Pandey
et al., 2009).
Angiotensin-II immunization (Table 4): The first active
immunization against angiotensin II in rats and rabbits was attempted in 1970.
Synthetic Ang II was coupled to Bovine serum albumin and emulsified in Freunds
adjuvant for better immunization. Although, immunization against Ang II was
showed a greater extent in reduction of response to exogenous Ang II, which
played no direct role in the production or maintenance of experimental renal
hypertension (Johnston et al., 1970).
Macdonald et al. (1970) used rabbits for study
and were immunized against Ang II. He was confirmed the specific absence of
pressor response to high doses of renin and Ang II after immunization. But there
was no evidence of modification in established hypertension.
Immunization against Ang II and combined Ang I and Ang II in rats was studied
by Oates et al. (1974) and he was confirmed that
those immunized equal parts Ang I and Ang II were found to develop antibodies
titre 6-15 times greater for Ang I than for Ang II. The sustained Ang I and
/or Ang II immunity did not alter blood pressure.
Angiotensin-I immunization (Table 4): Immunization
against Ang I in SHRs resulting in presence of high levels of antibodies against
Ang I, but still it is failed to reveal any fall in blood pressure during the
first 6 months time of immunization (Reade et al.,
Smits et al. (1999) showed no significant decrease
in mean blood pressure in immunized SHRs and the maintenance of the response
to Ang II antagonism. The only significant effect was an 11 mmHg decrease in
diastolic blood pressure during the sleeping period in immunized animals. Rats
were immunized against Ang I with an effective vaccine PMD-2850, which consists
of an Ang I analogue conjugated with a Tetanus Toxoid (TT) carrier protein adjuvant
with aluminum hydroxide. Anti-angiotensin antibody titre increased by 32,100
fold and these antibodies cross reacted with angiotensinogen and suppress the
ability of endogenous Ang I, then it would be expected to be more effective
than previous active immunizations. It had limited application due to epitopic
suppression (Gardiner et al., 2000).
The efficacy of keyhole limpet haemocyanin (KLH) (an alternative peptide carrier
protein) conjugated with Ang I vaccine (PMD-3117) to the earlier TT conjugated
vaccine (PMD-2850) is used to immunize rats and healthy human volunteers. Active
immunization of rats with immunogen containing Ang I conjugated with either
TT or KLH produced equivalent anti-Ang I-IgG titres and change in the dose response
to exogenous Ang I. Anti Ang I - IgG induction was not detected in humans with
given single doses of Ang ITT or Ang I-KLH conjugated vaccine but caused
production of anti-Ang I-IgG molecules when given in two doses of immunization
with AngI-KLH (Downham et al., 2003).
Phase IIa clinical trial was carried out in hypertensive subjects with anti-Ang
I vaccine (PMD-3117). One group of 8 patients received three doses of 100 μg
of vaccine at 21 days intervals, whereas a second group of 8 patients received
the same (100 μg) dose of vaccine on four occasions at 14 day intervals.
Twenty four patients completed all scheduled injections. Significant antibody
induction was detectable after the second injection with both regimes and were
not significantly different. It had no effect on blood pressure and it was assumed
that the titre generated by the formulation of the vaccine was too small to
provide sufficient AngI inhibition (Brown et al.,
In preclinical studies 6 SHRs were immunized against the peptide from rat AT1A
receptor by repeated subcutaneous injections of ATR12181 and observed for 64
weeks to assess its long-term efficacy, safety and its blood pressure lowering
ability. Repeated vaccinations resulted in the induction of anti-ATR12181 antibodies.
A 17 mmHg reduction of systolic blood pressure was observed in vaccinated SHRs
at the 64th week. However, the level of BP did not reach target level (140/90
mmHg). The long term results of vaccine ATR12181 in SHRs seemed to be encouraging
in all aspects like BP lowering, target organ remodeling, proving its efficacy
and safety (Zhu et al., 2006).
Vaccination against a self-antigen in which a peptide derived from AngII was
covalently conjugated to VLP (virus like particles) termed CYT006- AngQb (AngQb),
used to immunize SHRs and also human volunteers. Rats were injected subcutaneously
on days 0, 14 and 28 with 400 μg AngQb, immunization yielded a consistent
reduction in blood pressure lasting more than 35 days after the last boost.
In particular, no signs of inflammation were detected in the kidney, indicating
no inflammatory immune complex deposition. Human volunteers receiving single
dose subcutaneous injection of AngQb (100 μg) responded with high IgG titres
against AngII within 2 weeks of immunization but there was no significant changes
occurred in blood pressure. Fourteen out of 16 subjects showed local adverse
events such erythema, edema, pain and indurations at the injection site, all
of mild intensity. This clinical study was successful to show that AngQb vaccine
was highly immunogenic, induced no signs of inflammation or immune complex formation
and was tolerable (Ambuhl et al., 2007).
Multicenter, double-blind, randomized and placebo-controlled phase IIa trial
was conducted on 72 patients with mild-to-moderate hypertension, they were assigned
to receive injections of either AngQb 100 μg or 300 μg or placebo
in week 0, 4 and 12. All volunteers receiving AngQb responded with high IgG
titres against AngII after only one injection and the antibody response was
strongly boosted after the second injection. The 300 μg dose induced a
significantly higher AngII specific IgG response than 100 μg dose and the
average half-life after the third injection was 17 weeks. There was a significant
reduction of the early-morning BP surge compared with placebo in the 300 μg
group, postural hypertension was not seen. The vaccine was not associated with
any serious adverse effects. Interestingly, the drop in BP was pronounced in
the early morning, when the RAS is most active and when most stroke and cardiovascular
events occur (Tissot et al., 2008).
Ang I-R is an aluminum hydroxide adjuvant vaccine fprmulation targeted to Ang
I/II and administration of one dose of this results in production of strong
antibody response in SHRs. It has demonstrated sustained lowering of blood pressure
in SHRs (Hong et al., 2009).
Blockade of Rennin Angiotensin System (RAS): The RAS contributes to
maintenance of blood pressure during volume depletion (Adams,
2008). It has been argued that, it could cause problems after severe blood
loss from anti angiotensin antibody production and reduction of half-lives in
the range of several months.
Hypertension cannot be cured. It has to be managed throughout the life to avoid cardiovascular and renal complications. Management of hypertension with antihypertensive therapy requires a patients adherence to lifestyle modifications and medication. In most of the cases it requires polypharmacy, i.e., more than one drug to achieve desired goal, which may lead to various adverse effects. Hence immunization with vaccine would be a better alternative for antihypertensive drugs to overcome the problems related to compliance of the patient. Immunization against endogenous renin, angiotensin I and II could be an advantageous than antihypertensive therapy. Whereas there is also an incidence of autoimmune disorder due to excessive stimulation of immune system against endogenous substance released for maintaining homeostasis of body and undesired effects due to blockade of renin angiotensin system and it could be a major problem with vaccine for hypertension. It is better to use many excellent therapeutic options, which are already available to inhibit the RAS until efficient vaccine is developed.
1: Adams, J.U., 2008. Hypertension`s shot in the arm. Nature Biotechnol., 26: 1327-1329.
2: Akiyoshi, F., K. Sugimura, E. Takimoto, F. Sugiyama and M.S. Seo et al., 1993. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J. Biol. Chem., 268: 617-621.
Direct Link |
3: Ambuhl, P.M., A.C. Tissot, A. Fulurija, P. Maurer and J. Nussberger et al., 2007. A vaccine for hypertension based on virus-like particles: Preclinical efficacy and phase 1 safety and immunogenicity. J. Hypertens, 25: 63-72.
4: Beierwaltes, W.H., 2003. Renin Synthesis and Secretion. In: Hypertension Primer, Izzo, J.L. and H.R. Black (Eds.). Lippincott Williams and Wilkins, Philadelphia, pp: 14-17.
5: Berk, B.C. and M.A. Corson, 1997. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res., 80: 607-616.
6: Brown, M.J. J. Coltart, K. Gunewardena, J.M. Ritter, T.R. Auton and J.F. Glover, 2004. Randomized double blind placebo controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin. Sci., 107: 167-173.
Direct Link |
7: Brown, N.J. and D.E. Vaughan, 1998. Angiotensin-converting enzyme inhibitors. Circulation, 97: 1411-1420.
8: Burnier, M., 2001. Angiotensin II type 1 receptor blockers. Circulation, 103: 904-912.
9: Chobanian, A.V., G.L. Bakris, H.R. Black, W.C. Cushman and L.A. Green et al., 2003. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC7 Report. J. Am. Med. Assoc., 289: 2560-2572.
Direct Link |
10: Downham, M.R., T.R. Auton, A. Rosul, H.L. Sharp and L. Sjostrom et al., 2003. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br. J. Clin. Pharmacol., 56: 505-512.
11: Duff, J.L., M.B. Marrero and W.G. Paxton, 1995. Angiotensin II signal transduction and the mitogen activated protein kinase pathway. Cardiovasc Res., 30: 511-517.
12: Duncan, J.C., 2009. Renin inhibitors mechanisms of action. Aust. Prescr., 32: 132-135.
13: Duprez, D.A., 2006. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J. Hypertens., 24: 983-991.
14: Franklin, S.S., M.G. Larson, S.A. Khan, N.D. Wong, E.P. Leip, W.B. Kannel and D. Levy, 2001. Does the relation of blood pressure to coronary heart disease risk change with aging? The framingham heart study. Circulation, 103: 1245-1249.
Direct Link |
15: Gardiner, S.M., T.R. Auton, M.R. Downham, H.L. Sharp and P.A. Kemp et al., 2000. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br. J. Pharmacol., 129: 1178-1182.
CrossRef | Direct Link |
16: Goldblatt, H., 1951. Antirenin in man and animals. Trans. Assoc. Am. Physicians., 64: 122-122.
17: He, J., P.K. Whelton, L.J. Appel, J. Charleston and M.J. Klag, 2000. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension, 35: 544-549.
Direct Link |
18: Hong, F., W.Y. Hong, R. Pandey, S. yi and L. Chi et al., 2009. A vaccine for hypertension based on peptide AngI-R: A pilot study. Int. J. Cardiol., 10.1016/j.ijcard.2009.10.027
19: Johnston, C.I., J.S. Hutchinson and F.A. Mendelsohn, 1970. Biological significance of renin-angiotensin immunization. Circ. Res., 26: 215-222.
20: Macdonald, G.J., W.J. Louis, V. Renzini, G.W. Boyd and W.S. Peart, 1970. Renal clip hypertension in rabbits immunized against angiotensin II. Circ Res., 27: 197-197.
Direct Link |
21: Mancia, G., G. de Backer, A. Dominiczak, R. Cifkova, R. Fagard and G. Germano et al., 2007. Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens, 25: 1105-1187.
22: Maurer, P. and M.F. Bachmann, 2010. Immunization against angiotensins for the treatment of hypertension. Clin. Immunol., 134: 89-95.
23: Michel, J.B., S. Sayah, C. Guettier, J. Nussberger and M. Philippe et al., 1990. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation, 81: 1899-1910.
Direct Link |
24: Michel, J.B., C. Guettier, R. Reade, S. Sayah and P. Corvol, 1989. Immunologic approaches to blockade of the renin angiotensin system: A review. Am. Heart J., 117: 756-767.
25: Oates, H.F., G.S. Stokes, B.G. Storey, R.G. Glover and B.F. Snow, 1974. Renal hypertension in rats immunized against angiotensin I and angiotensin II. J. Exp. Med., 139: 239-248.
26: Pandey, R., W.Y. Quan, F. Hong and L. Jie, 2009. Vaccine for hypertension: Modulating the renin-angiotensin system. Int. J. Cardiol., 134: 160-168.
Direct Link |
27: Reade, R., J.B. Michel, С. Carelli, H. Huang, T. Baussant and P. Corvol, 1989. Immunization of spontaneously hypertensive rats against angiotensin 1. Arch. Mal. Coeur. Vaiss, 82: 1323-1328.
28: Schmieder, R.E., K.F. Hilgers, M.P. Schlaich and B.M.W. Schmidt, 2007. Overview of the renin-angiotensin system. Korean Circulation J., 37: 91-96.
29: Sathyanaryana, S., M.S. Chandrashekar, G.O. Palakshi and K. E. Kumar, 2008. Drug-drug interaction between pravastatin and gliclazide in animal models. Scholarly Res. Exchange, 10.3814/2008/620489
30: Sica, D.A., 2002. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs, 62: 443-462.
31: Smits, J., T. Auton, J. Sharp, M. Downham, J. Glover and B. Janssen, 1999. Antihypertensive properties of angiotensin immunotherapeutic in spontaneous hypertension in rats. FASEB J., 13: A48-A48.
32: Suh, S.Y., C.G. Park, U.R. Chwe, J.W. Kim, S.W. Rha and H.S. Seo, 2005. Plasma renin activity and clinical implication in Korean hypertensive patients. Korean Circ. J., 35: 658-664.
33: Sultanpur, C.M., S. Satyanarayana, N.S. Reddy, K.E. Kumar and S. Kumar, 2010. Drug-Drug interaction between pravastatin and gemfibrozil (Antihyperlipidemic) with gliclazide (Antidiabetic) in rats. J. Young Pharm., 2: 152-155.
Direct Link |
34: Tissot, A.C., P. Maurer, J. Nussberger, R. Sabat and T. Pfister et al., 2008. Effect of immunizations against angiotensin II with CYT006-AngQb on ambulatory blood pressure: A double-blind, randomized, placebocontrolled phase IIa study. Lancet, 371: 821-827.
35: Ulfendahl, H.R. and M. Aurell, 1998. Renin-Angiotensin: a Centenary Symposium of the Discovery of the Renin-Angiotensin System. Portland Press, London, pp: 1-12.
36: Unger, T., J. Culman and P. Gohlke, 1998. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J. Hypertens, 16: S3-S9.
37: Whelton, P.K., J. He, I.J. Appel, J.A. Cutlers, S. Harras and T.A. Kotchen, 2002. Primary prevention of hypertension, clinical and public health advisory from the National High Blood Pressure Education Program. JAMA., 288: 1882-1888.
Direct Link |
38: Zhu, F., Y.H. Liao, L.D. Li, M. Cheng and F. Wei et al., 2006. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR 12181 in spontaneously hypertensive rats. Cell Mol. Immunol., 3: 107-114.